Novartis's Sandoz licenses proposed multiple sclerosis biosimilar

Novartis's Sandoz licenses proposed multiple sclerosis biosimilar

9:22 AM, 3rd September 2019
Novartis logo
Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland. Photo: Reuters

ZURICH: Swiss drugmaker Novartis's Sandoz division has licensed from Polpharma Biologicsproposed biosimilar version of multiple sclerosis drug natalizumab, the companies said on Tuesday without giving financial details of the accord.

The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).

Polpharma Biologics will develop, manufacture and supply the drug, while Sandoz will commercialise and distribute the medicine in all markets through an exclusive global license.

Natalizumab, already on the market for a decade, is sold by Biogen Inc as Tsybari.

Pierre Bourdage, interim head of biopharmaceuticals at Sandoz, said the deal could help provide more multiple sclerosis patients with treatment.

"With this agreement, we hope to build on our MS experience with small molecules and complex generics and ultimately provide patients with expanded access to a (disease-modifying treatment) that healthcare systems may otherwise not be able to provide," he said.

Novartis last week stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus.

Source: Reuters  



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Clariant, Wuxi Xiyuan to provide innovative tail gas treatment solutions in China

SHANGHAI, CHINA/MUNICH, GERMANY: Clariant said that its catalyst business unit has further cooperated with Wuxi Xiyuan Engineering Technology Co Ltd, ...

Read more
Bayer completes sale of Coppertone brand to Beiersdorf

LEVERKUSEN, GERMANY: Bayer AG has completed the sale of the Coppertone brand to Beiersdorf for a purchase price of $550 million. Having successfully c ...

Read more
Major fire breaks out at ONGC’s Navi Mumbai factory: 5 killed, 3 injured

MUMBAI, INDIA: At least five persons were killed and three others injured after a fire broke out at the Oil and Natural Gas Corporation's (ONGC) plant ...

Read more
Aurobindo Pharma arm forms JV in China

NEW DELHI, INDIA: Drug firm Aurobindo Pharma said its arm Helix Healthcare B V, Netherlands has entered into an agreement with Chinese firm Shanghai L ...

Read more
Chemical factory explosion kills 10, injures 40 in Maharashtra, India

DHULE, INDIA: At least 10 workers were killed and 40 injured in an explosion of gas cylinders at a chemical factory in Dhule district of Maharashtra, ...

Read more
Quaker Houghton to acquire operating divisions of Norman Hay

CONSHOHOCKEN, US: Quaker Houghton has agreed to acquire the operating divisions of Norman Hay plc, a private UK company that provides specia ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X